On this page
KCNJ11
potassium inwardly rectifying channel subfamily J member 11
KCNJ11 is located on the short (p) arm of chromosome 11, at band 11p15.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 11 in the library →Available at Jeen Health
Clinical tests that include this
Overview
KCNJ11 (potassium inwardly rectifying channel subfamily J member 11) encodes the Kir6.2 protein, which forms part of the ATP-sensitive potassium channel complex in pancreatic beta cells. These channels play a central role in glucose homeostasis by linking metabolic signals to insulin secretion. The protein works together with another subunit encoded by the ABCC8 gene to form functional channels that span the beta cell membrane.
Variants in KCNJ11 can cause several inherited conditions affecting blood glucose control. Depending on how the variant affects channel function, individuals may experience either inappropriately low blood glucose (hyperinsulinism) or elevated glucose levels (diabetes). The gene is included in multiple NHS Genomic Medicine Service panels for diabetes and hyperinsulinism, reflecting its clinical significance in glucose regulation disorders.
What the gene does
The Kir6.2 protein produced by KCNJ11 assembles with four subunits from the ABCC8 gene to create ATP-sensitive potassium channels. These octameric structures function as metabolic sensors in pancreatic beta cells, where they regulate the cell's electrical activity and thereby control insulin release.
When blood glucose levels rise, glucose enters beta cells and undergoes metabolism, increasing the ratio of ATP to ADP within the cell. This elevated ATP binds to the channel complex, causing it to close. Channel closure prevents potassium ions from leaving the cell, which depolarises the cell membrane. This depolarisation triggers voltage-gated calcium channels to open, allowing calcium influx that stimulates insulin-containing granules to fuse with the cell membrane and release insulin into the bloodstream.
Conversely, when glucose levels are low, reduced ATP allows the channels to remain open, maintaining the cell in a hyperpolarised state that prevents insulin secretion. This molecular switch ensures that insulin release is tightly coupled to metabolic demand, maintaining appropriate blood glucose levels throughout the day.
Video: Genetics 101
Chromosome location
KCNJ11 is located on chromosome 11 at position p15.1, in the short arm of the chromosome. The gene lies immediately adjacent to ABCC8, which encodes its obligate channel partner. This genomic proximity reflects the functional relationship between the two genes, as their protein products must assemble together to form functional ATP-sensitive potassium channels.
Protein structure
The KCNJ11 protein comprises 390 amino acids that fold into a structure characteristic of inwardly rectifying potassium channels. The protein contains two transmembrane segments connected by an extracellular loop, with both the N-terminus and C-terminus located in the cytoplasm. The selectivity filter, spanning amino acids 130-135, forms the narrow constriction of the channel pore that allows potassium ions to pass whilst excluding other ions. This motif contains the highly conserved sequence that determines the channel's ion selectivity, ensuring that only potassium ions can traverse the pore efficiently. Four Kir6.2 subunits combine with four ABCC8 subunits to create the complete functional channel.
Key variants
Pathogenic variants in KCNJ11 typically alter single amino acids in the protein sequence, affecting how the channel responds to ATP or changes its baseline open-closed equilibrium. Variants that impair channel closure lead to excessive insulin secretion and hypoglycaemia, whilst those that prevent normal channel closure cause reduced insulin release and hyperglycaemia. The clinical consequences depend on the specific functional effect of each variant.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.100C>T | p.Arg34Cys | Pathogenic/Likely pathogenic | ★★☆☆ | Familial hyperinsulinism |
c.101G>A | p.Arg34His | Pathogenic/Likely pathogenic | ★★☆☆ | Hyperinsulinemic hypoglycemia, familial, 2 |
c.160dup | p.Arg54fs | Pathogenic/Likely pathogenic | ★★☆☆ | Diabetes mellitus, permanent neonatal 2 |
c.406C>T | p.Arg136Cys | Pathogenic/Likely pathogenic | ★★☆☆ | Type 2 diabetes mellitus |
c.407G>T | p.Arg136Leu | Pathogenic/Likely pathogenic | ★★☆☆ | Familial hyperinsulinism |
c.556C>G | p.His186Asp | Pathogenic/Likely pathogenic | ★★☆☆ | Permanent neonatal diabetes mellitus |
c.560C>T | p.Ala187Val | Pathogenic/Likely pathogenic | ★★☆☆ | Familial hyperinsulinism |
c.616C>T | p.Arg206Cys | Pathogenic/Likely pathogenic | ★★☆☆ | KCNJ11-related disorder |
c.617G>A | p.Arg206His | Pathogenic/Likely pathogenic | ★★☆☆ | Familial hyperinsulinism |
c.901C>G | p.Arg301Gly | Pathogenic/Likely pathogenic | ★★☆☆ | Familial hyperinsulinism |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
KCNJ11 variants are associated with several conditions affecting glucose regulation. Neonatal diabetes (KCNJ11) typically presents within the first six months of life with persistently elevated blood glucose; some affected individuals also develop neurological features. Congenital hyperinsulinism (both diffuse and focal forms, KATP) manifests with recurrent episodes of dangerously low blood glucose due to unregulated insulin secretion. Additionally, common variation in KCNJ11 contributes to the polygenic risk architecture of type 2 diabetes mellitus, though individual variants typically confer modest effects.
- Congenital hyperinsulinism (diffuse, KATP)
- Type 2 diabetes mellitus
- Congenital hyperinsulinism (focal) Dedicated page coming soon
- Neonatal diabetes (KCNJ11) Dedicated page coming soon
Inheritance pattern
Conditions caused by pathogenic KCNJ11 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
KCNJ11 holds green (diagnostic-grade evidence) classification across multiple NHS Genomic Medicine Service panels. These include the Monogenic diabetes panel (R141), Neonatal diabetes panel (R143), Congenital hyperinsulinism panel (R144), and Familial diabetes panel. The gene also appears on panels for Diabetes with additional phenotypes suggestive of a monogenic aetiology, Early onset or syndromic epilepsy (R59), and Intellectual disability (R29), reflecting the broader phenotypic spectrum associated with some KCNJ11 variants. This extensive panel representation underscores the gene's clinical utility in diagnosing glucose regulation disorders.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the difference between KCNJ11-related diabetes and type 2 diabetes?
KCNJ11-related neonatal diabetes is a monogenic condition caused by variants in a single gene, typically presenting within the first six months of life. Type 2 diabetes is a polygenic condition influenced by many genes and environmental factors, usually developing in adulthood. Some individuals with neonatal diabetes caused by specific KCNJ11 variants can be treated with sulphonylurea medications rather than insulin.
How do KCNJ11 variants cause opposite effects on blood glucose?
Different variants affect channel function in opposite ways. Variants that prevent the channel from closing properly cause excessive insulin secretion, leading to hypoglycaemia (congenital hyperinsulinism). Variants that prevent the channel from opening normally reduce insulin secretion, causing hyperglycaemia (diabetes). The specific functional consequence depends on where the variant occurs in the protein and how it alters channel activity.
Why is KCNJ11 on epilepsy and intellectual disability panels?
Some KCNJ11 variants cause a condition called DEND syndrome (developmental delay, epilepsy, and neonatal diabetes), in which affected individuals experience neurological features in addition to diabetes. ATP-sensitive potassium channels encoded by KCNJ11 are also present in neurons and muscle, so variants affecting channel function can have effects beyond the pancreas.
References
- Rubio-Cabezas O, Klupa T, Malecki MT. Permanent neonatal diabetes mellitus--the importance of diabetes differential diagnosis in neonates and infants. European journal of clinical investigation. 2011. PMID: 21054355
- Bennett K, James C, Hussain K. Pancreatic β-cell KATP channels: Hypoglycaemia and hyperglycaemia. Reviews in endocrine & metabolic disorders. 2010. PMID: 20878482
- Flanagan SE, Clauin S, Bellanné-Chantelot C. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Human mutation. 2009. PMID: 18767144
- James C, Kapoor RR, Ismail D. The genetic basis of congenital hyperinsulinism. Journal of medical genetics. 2009. PMID: 19254908
- Reyes S, Park S, Johnson BD. KATP channel Kir6.2 E23K variant overrepresented in human heart failure is associated with impaired exercise stress response. Human genetics. 2009. PMID: 19685080
- Polak M, Cavé H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet journal of rare diseases. 2007. PMID: 17349054
- Gloyn AL, Siddiqui J, Ellard S. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Human mutation. 2006. PMID: 16416420
- Flanagan SE, Edghill EL, Gloyn AL. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia. 2006. PMID: 16609879